Teva Pharmaceutical Industries Ltd

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022🗂️ Report periods on file: 2022

In its 2022 reporting, Teva Pharmaceutical Industries Ltd disclosed greenhouse gas emissions of 498.6K tCO2e/year (Scope 1 & 2 in 2022). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
498.6K tCO2e/year (Scope 1 & 2 in 2022)
2022
⚡
Renewable Energy
41%
of total energy
♻️
Waste
42.6K metric tons of hazardous waste and 68593 metric tons of non-hazardous waste in 2022
2022

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce absolute scope 1 and 2 GHG emissions by 25% by 2025 (vs. 2019)
  • Train 100% of employees on compliance policies by 2023
  • Assess 100% of critical suppliers on ESG performance by 2025

📅 Medium-term

  • Reduce absolute scope 1 and 2 GHG emissions by 46% by 2030 (vs. 2019)
  • Reduce absolute scope 3 GHG emissions by 25% by 2030 (vs. 2020)
  • Increase renewable energy share to 50% by 2030
  • Reduce water withdrawal by 10% in water-stressed areas by 2030 (vs. 2020)
  • Increase access to medicine program product volume by 150% in 2025 (vs. 2020)

🔭 Long-term

  • Net-zero emissions

🌱 ESG Focus Areas

Climate Action and ResilienceAccess to Health and MedicinesInclusion and DiversityCompliance and EthicsQuality Manufacturing and Patient SafetySustainable Procurement

⚠️ Challenges & Risks +

  • Supply chain disruptions
  • Climate change impacts
  • Competition in the pharmaceutical market
  • Managing ESG risks across the global supply chain
  • Addressing the opioid crisis

📋 Report Information

Reporting Period: 2022
Frameworks: GRI, SASB, TCFD, UNGC
Assurance: DNV